Opportunity Information: Apply for PAR 10 216

  • The National Institutes of Health in the health sector is offering a public funding opportunity titled "Novel NeuroAIDS Therapeutics Integrated Preclinical/Clinical Program (P01)" and is now available to receive applicants.
  • Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants.
  • This funding opportunity was created on Jun 16, 2010 and posted on Jun 16, 2010.
  • Applicants must submit their applications by Sep 7, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
  • Eligible applicants include: Small businesses Public housing authorities/Indian housing authorities Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governments Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Independent school districts For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) State governments Public and State controlled institutions of higher education Private institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification).
  • Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
Apply for PAR 10 216

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:

Opportunity Summary:

The Novel NeuroAIDS Therapeutics Integrated Preclinical/Clinical Program (P01) grant opportunity (Funding Opportunity Number PAR-10-216) is a National Institutes of Health program led by the National Institute of Mental Health that is aimed squarely at speeding up the discovery and development of new drug-based treatments for HIV Associated Neurocognitive Disorders (HAND). The central motivation behind the announcement is the persistent clinical reality that a large share of people living with HIV continue to show neurocognitive impairment even while taking highly active antiretroviral therapy (HAART). In other words, controlling systemic viral replication with standard antiretrovirals has not eliminated the burden of cognitive and neurologic complications for many patients, which points to gaps in current biological understanding and a need for therapies that specifically target the mechanisms driving HAND or its progression.

This FOA is built around the idea that meaningful progress will require an intentionally integrated pipeline that connects basic science, translational studies, and steps that move therapeutic candidates closer to clinical readiness. Applicants are expected to propose a coordinated, multidisciplinary program that goes beyond a set of loosely related projects. The structure must include at least three highly integrated research projects plus a required Administrative Core. The overall program should be organized around the common goal of identifying, developing, and advancing novel therapeutic drug candidates for HAND, including the kind of work that typically supports therapeutic advancement such as mechanistic studies, target identification and validation, preclinical testing strategies, and translational planning that makes eventual clinical evaluation more realistic.

A notable feature of the opportunity is that it explicitly encourages or permits industry participation: at least one of the research components can be derived from an industry partner such as a pharmaceutical, chemical, bioengineering, or biotechnology company. This signals an interest in leveraging capabilities that are often stronger in industry settings (for example, medicinal chemistry, formulation, pharmacokinetics, scalable manufacturing concepts, or certain regulatory and development expertise), while keeping the broader program anchored in a collaborative P01 framework that integrates academic and other research environments.

From a governance and oversight standpoint, each funded award will have a Scientific Advisory Panel (SAP) put in place within six months of the award start. That requirement implies NIH expects active external scientific input to help keep large, multi-project programs aligned with milestones, translational relevance, and the overall therapeutic development mission. The Administrative Core is therefore not just a formality; it is intended to provide the management backbone for coordination across projects, communication, progress tracking, and engagement with advisory input.

The funding mechanism is the NIH Program Project Grant (P01), which is designed for large, multi-component projects where the parts are interdependent and share a unifying theme. Consistent with how P01s operate, the size and duration of awards are not fixed in the announcement summary and are expected to vary depending on what an application proposes and how broad or complex the integrated program is. Likewise, NIH indicates that awards depend on available funds and on the submission of a sufficient number of meritorious applications, meaning there is no guaranteed number of awards.

In terms of eligibility, the opportunity is broadly open across many organization types, including public and private institutions of higher education, nonprofits (including 501(c)(3) and non-501(c)(3) entities), small businesses and other for-profit organizations (with distinctions noted), state and local governments, tribal governments and tribal organizations, U.S. territories or possessions, and a range of mission-relevant institution types such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, faith-based or community-based organizations, and even non-U.S. (foreign) entities and regional organizations where applicable. The FOA states there is no cost-sharing or matching requirement, which is typical for many NIH research grant mechanisms.

Key administrative details in the source data include that the opportunity falls under the health funding activity category and is associated with CFDA number 93.242 (Mental Health Research Grants). The announcement was posted and created on June 16, 2010, with an original and current closing date of September 7, 2012, and an archive date of October 8, 2012, indicating the opportunity is historical rather than currently open. The full announcement is referenced through the NIH Grants Guide link (http://grants.nih.gov/grants/guide/pa-files/PAR-10-216.html), and NIH provides contact pathways through the NIH Office of Extramural Research webmaster for access or technical linking issues.

Frequently Asked Questions (FAQs)

What is the Novel NeuroAIDS Therapeutics Integrated Preclinical/Clinical Program (P01)?

It is an NIH Program Project Grant (P01) opportunity focused on accelerating the discovery and development of new drug-based treatments for HIV Associated Neurocognitive Disorders (HAND). The program is designed to connect basic, translational, and preclinical-to-clinical planning work into one coordinated, milestone-oriented pipeline.

What is the Funding Opportunity Number (FON) for this announcement?

The Funding Opportunity Number is PAR-10-216.

Which NIH institute leads this program?

The program is led by the National Institute of Mental Health (NIMH).

What health problem is this FOA trying to address?

The FOA targets HIV Associated Neurocognitive Disorders (HAND), motivated by the continuing reality that many people living with HIV experience neurocognitive impairment even while receiving highly active antiretroviral therapy (HAART). The program is intended to address gaps in understanding and treatment by developing therapeutics that specifically target mechanisms driving HAND or its progression.

Why does this FOA emphasize new therapeutics if antiretroviral therapy controls HIV replication?

The announcement highlights that controlling systemic viral replication with standard antiretrovirals has not eliminated cognitive and neurologic complications for a substantial share of patients. This suggests a need for therapies aimed at the specific biological mechanisms involved in HAND.

What type of grant mechanism is used?

This opportunity uses the NIH Program Project Grant mechanism (P01), which supports large, multi-component research programs where the projects are interdependent and organized around a unifying theme.

What is the expected overall approach for applications?

Applications are expected to propose a coordinated, multidisciplinary program with an intentionally integrated pipeline spanning basic science and translational efforts, and advancing therapeutic candidates toward clinical readiness. The FOA indicates it is not intended to support a collection of loosely related projects.

How many research projects are required in the P01 structure?

The structure must include at least three highly integrated research projects.

Is an Administrative Core required?

Yes. A required Administrative Core must be included.

What is the purpose of the Administrative Core in this FOA?

The Administrative Core is intended to provide the management backbone for coordinating projects, supporting communication, tracking progress, and facilitating engagement with advisory input. It is positioned as a key part of keeping the integrated program functioning as a unified pipeline.

What kinds of research activities does the FOA expect to see in the program?

Based on the description provided, expected activities include work that supports therapeutic advancement such as mechanistic studies, target identification and validation, preclinical testing strategies, and translational planning that makes eventual clinical evaluation more realistic. The common goal should be identifying, developing, and advancing novel therapeutic drug candidates for HAND.

Does this FOA allow or encourage industry involvement?

Yes. The opportunity explicitly encourages or permits industry participation, and indicates that at least one research component can be derived from an industry partner (for example, a pharmaceutical, chemical, bioengineering, or biotechnology company).

What might industry partners contribute within this program structure?

The FOA signals interest in leveraging industry strengths such as medicinal chemistry, formulation, pharmacokinetics, scalable manufacturing concepts, or regulatory and development expertise, while still operating within a collaborative P01 framework integrated with academic and other research environments.

Is there an oversight or advisory requirement after an award is made?

Yes. Each funded award is required to establish a Scientific Advisory Panel (SAP) within six months of the award start.

What does the requirement for a Scientific Advisory Panel (SAP) suggest about NIH expectations?

It implies NIH expects active external scientific input to help keep multi-project programs aligned with milestones, translational relevance, and the therapeutic development mission described in the FOA.

Are award size and project period fixed for this FOA?

No. The summary indicates award size and duration are not fixed and are expected to vary depending on what an application proposes and how broad or complex the integrated program is.

Are awards guaranteed if an application is submitted?

No. NIH indicates awards depend on available funds and on the submission of a sufficient number of meritorious applications, and there is no guaranteed number of awards.

Is cost sharing or matching required?

No. The FOA states there is no cost-sharing or matching requirement.

Who is eligible to apply?

Eligibility is described as broad and includes (among others): public and private institutions of higher education; nonprofits (including 501(c)(3) and non-501(c)(3) organizations); small businesses and other for-profit organizations (with distinctions noted); state and local governments; tribal governments and tribal organizations; U.S. territories or possessions; and mission-relevant institution types such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, faith-based or community-based organizations; as well as non-U.S. (foreign) entities and regional organizations where applicable.

What is the funding activity category and CFDA number associated with this opportunity?

The funding activity category is health. The opportunity is associated with CFDA 93.242 (Mental Health Research Grants).

Is this funding opportunity currently open?

No. The dates provided indicate it is historical: it was posted/created on June 16, 2010; the original and current closing date is September 7, 2012; and the archive date is October 8, 2012.

Where can the full announcement be found?

The full announcement is referenced via the NIH Grants Guide at http://grants.nih.gov/grants/guide/pa-files/PAR-10-216.html.

Who should be contacted for access or technical linking issues related to the announcement?

NIH provides contact pathways through the NIH Office of Extramural Research webmaster for access or technical linking issues.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: Asthma and Allergic Diseases Cooperative Research Centers (U19)

Previous opportunity: Expanding and Personalizing Treatment Options for Alcohol Use Disorders Including Pharmacogenomics (R01)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAR 10 216

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAR 10 216) also looked into and applied for these:

Funding Opportunity
Asthma and Allergic Diseases Cooperative Research Centers (U19) Apply for RFA AI 10 013

Funding Number: RFA AI 10 013
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Emergency Countermeasure Dispensing Staffing Plan Apply for CDC RFA TP10 1002

Funding Number: CDC RFA TP10 1002
Agency: Centers for Disease Control and Prevention
Category: Health
Funding Amount: $300,000
Terrorism Injuries Information Dissemination and Exchange (TIIDE) Apply for CE07 70301SUPP10

Funding Number: CE07 70301SUPP10
Agency: Centers for Disease Control and Prevention
Category: Health
Funding Amount: Case Dependent
ACA Advanced Nursing Education Expansion Program Apply for HRSA 10 281

Funding Number: HRSA 10 281
Agency: Health Resources and Services Administration
Category: Health
Funding Amount: Case Dependent
Affordable Care Act (ACA) Nurse Managed Health Clinics Apply for HRSA 10 282

Funding Number: HRSA 10 282
Agency: Health Resources and Services Administration
Category: Health
Funding Amount: Case Dependent
ACA Expansion of Physician Assistant Training Program Apply for HRSA 10 278

Funding Number: HRSA 10 278
Agency: Health Resources and Services Administration
Category: Health
Funding Amount: Case Dependent
Affordable Care Act State Health Care Workforce Planning Grants Apply for HRSA 10 284

Funding Number: HRSA 10 284
Agency: Health Resources and Services Administration
Category: Health
Funding Amount: $150,000
Primary Care Residency Expansion Apply for HRSA 10 277

Funding Number: HRSA 10 277
Agency: Health Resources and Services Administration
Category: Health
Funding Amount: Case Dependent
Affordable Care Act State Health Care Workforce Implementation Grants Apply for HRSA 10 285

Funding Number: HRSA 10 285
Agency: Health Resources and Services Administration
Category: Health
Funding Amount: Case Dependent
Affordable Care Act Personal and Home Care Aide State Training Program Apply for HRSA 10 288

Funding Number: HRSA 10 288
Agency: Health Resources and Services Administration
Category: Health
Funding Amount: $750,000
Supportive Environments for Healthy Households and Communities Apply for RFA OAA 10 000008

Funding Number: RFA OAA 10 000008
Agency: Agency for International Development
Category: Health
Funding Amount: $100,000,000
Strengthening the Ministry of Health s Capacity to Respond to the HIV/AIDS Epidemic in the Republic of Rwanda under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS09 911801SUPP11

Funding Number: CDC RFA PS09 911801SUPP11
Agency: Centers for Disease Control and Prevention
Category: Health
Funding Amount: Case Dependent
Affordable Care Act (ACA) Nursing Assistant and Home Health Aide Program Apply for HRSA 10 273

Funding Number: HRSA 10 273
Agency: Health Resources and Services Administration
Category: Health
Funding Amount: $250,000
FY10 Project HOPE Helping Organizations Provide Effective HIV/AIDS Prevention for Women and Girls A Capacity Building and Technical Assistance Cooperative Agreement Apply for WH MPP 10 001

Funding Number: WH MPP 10 001
Agency: Office of the Assistant Secretary for Health
Category: Health
Funding Amount: $500,000
FY10 Health and Wellness Initiative for Women Attending Minority Institutions Apply for WH HPP 10 002

Funding Number: WH HPP 10 002
Agency: Office of the Assistant Secretary for Health
Category: Health
Funding Amount: $100,000
Prevention of Mother to Child Transmission (PMTCT) Program in Swaziland Apply for 674 10 00040

Funding Number: 674 10 00040
Agency: South Africa USAID Pretoria
Category: Health
Funding Amount: $12,000,000
Behavior Change Communication for Infectious Disease Prevention Apply for USAID RDMA 486 10 024 RFA

Funding Number: USAID RDMA 486 10 024 RFA
Agency: Thailand USAID Bangkok
Category: Health
Funding Amount: $36,000,000
Cancer Survivorship Resource Center Apply for CDC RFA DP10 1015

Funding Number: CDC RFA DP10 1015
Agency: Centers for Disease Control and Prevention
Category: Health
Funding Amount: $850,000
Subjective Well being Advances in Measurement and Applications to Aging (R01) Apply for RFA AG 11 003

Funding Number: RFA AG 11 003
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Regional and International Differences in Health and Longevity at Older Ages (R01) Apply for RFA AG 11 004

Funding Number: RFA AG 11 004
Agency: National Institutes of Health
Category: Health
Funding Amount: $330,000

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

USGrants.org applicant portal membership

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAR 10 216", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.